ClinicalTrials.gg
Active, not recruitingNCT03611270TROPHY-IIUpdated Aug 21, 2023

TReatment of Pulmonary Hypertension Group II Study

An interventional study of Pulmonary Denervation in Pulmonary Hypertension (PH) Due to Left Heart Disease, sponsored by SoniVie Inc.. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by SoniVie Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 397 studies in Hypertension, Pulmonary with a site in United States — 72 open to participants now, 86 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.

Planned enrollment
195th of 286
15 · median 30
Started
2018
with 18 others
No phase
42 of 397
12 open now
Primary completion
2023-12
later than 2 of 84 live
Registered
266th of 397
by date

Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 195th largest by planned enrollment of the 286 interventional ones that give a count, is one of 19 that started in 2018, is one of 42 with no phase, reaches primary completion later than 2 of the 84 other live ones, and was the 266th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

72 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 397 studies in Hypertension, Pulmonary with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety and initial effectiveness of the TIVUS™ System when used for pulmonary artery denervation in group II PH patients through change in clinical parameters including hemodynamics, exercise tolerance, and quality of life.

This is a prospective, multi-center, non-randomized, open-label clinical trail. The study will be conducted in up to 3 centers and will recruit up to 15 patients diagnosed with pulmonary hypertension due to left heart disease that demonstrate combined pre and post capillary involvement with PVR>3 wood units.

03

Conditions studied

  • Pulmonary Hypertension (PH) Due to Left Heart Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written to participate in the study obtained from the patient, according to local regulations, prior to initiation of any study mandated procedure.
  • Male or female, ≥ 18 years of age at the time of screening
  • Patient with known pulmonary hypertension (PH) due to left heart disease (WHO Group II) diagnosed as either HFpEF or HFrEF at chronic state receiving stable guideline directed medical therapy.
  • Combined post-capillary and precapillary pulmonary hypertension diagnosis confirmed by hemodynamic evaluation performed prior to screening or during baseline (Eligibility II visit) procedure
  • Patient with a current diagnosis of functional class II/III
  • Patient with levels of ≥ 30 ml/min/1.73m2or serum creatinine levels of ˂ 150μmol/l

Exclusion criteria

Exclusion Criteria:

  • Pregnant women or women planning a pregnancy within 12 months of study enrolment
  • Patient with significant co-morbid condition(s) which, at the discretion of the PI, are deemed to prohibit study entry
  • Patient with of less than a year
  • Concurrent enrollment in another device or drug trial except for observational studies (unless specifically approved by the sponsor)
  • Patient with pulmonary artery anatomy that precludes treatment
  • Patient with moderate to severe pulmonary artery stenosis
  • Patient with any pulmonary artery aneurysm
  • Patient who has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident in the previous 6 months
  • Patient experiencing a current episode of acute decompensated heart failure
  • Patient who has cardiac pacemakers/ICD/CRT-D that were implanted fewer than three months prior to enrolment. Patient who has implantable Cardiomems device, neurostimulators or drug infusion devices, regardless of implant date.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Interventions

  • DevicePulmonary Denervation

    Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.

06

What researchers measure

Primary outcomes

  1. Procedural related Adverse Events (complications) at up to 30 days post procedure

    Procedural related Adverse Events (complications) at up to 30 days post procedure including pulmonary artery perforation/dissection, acute thrombus formation in the pulmonary artery, pulmonary artery aneurysm, vascular stenosis, hemoptysis, all cause PH related as well as procedural related death.

    Time frame: 30 days

Secondary outcomes

  1. Changes in cardiopulmonary exercise test

    Changes in cardiopulmonary exercise test (CPET) results (Peak VO2, VE/VCO2 slope, VO2 at anaerobic threshold, peak workload) from baseline

    Time frame: 4 month

  2. Change in resting mean right atrial pressure

    Change in resting mean atrial pressure (mRAP) from baseline

    Time frame: 4 month

  3. Changes in 6MWD from baseline

    Changes in 6MWD from baseline

    Time frame: 4 month

  4. Changes in Echocardiography parameters

    Changes in Echocardiography parameters including Right Ventricular function from baseline

    Time frame: 4 month

  5. Change in NT-BNP levels

    Change in NT-BNP levels from baseline

    Time frame: 4 month

  6. Procedure related and PH worsening adverse events

    Procedure related and PH worsening adverse events and all cause death up to 12 months will be recorded, and serious adverse events will be reported in accordance with regulatory requirements.

    Time frame: 12 month

  7. Change in exercise mean right atrial pressure

    Change in exercise mean right atrial pressure (mRAP) from baseline

    Time frame: 4 month

  8. Change in exercise mean pulmonary artery pressure

    Change in exercise mean pulmonary artery pressure (mPAP) from baseline

    Time frame: 4 month

  9. Change in exercise pulmonary vascular resistance

    Change in exercise pulmonary vascular resistance (PVR) from baseline

    Time frame: 4 month

  10. Change in exercise cardiac index

    Change in exercise cardiac index (CI) from baseline

    Time frame: 4 month

  11. Change in resting mean pulmonary artery pressure

    Change in resting mean pulmonary artery pressure (mPAP) from baseline

    Time frame: 4 month

  12. Change in resting pulmonary vascular resistance

    Change in resting pulmonary vascular resistance (PVR) from baseline

    Time frame: 4 month

  13. Change in resting cardiac index

    Change in resting cardiac index (CI) from baseline

    Time frame: 4 month

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2018 (actual). Primary completion is estimated for Dec 2023, 60 months after the start.

Of 150 interventional studies with no phase under Hypertension, Pulmonary, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 48. This study's planned 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2018
First posted
Aug 2, 2018
StartActual
Nov 30, 2018
Primary completionEst.
Dec 1, 2023
CompletionEst.
Jul 2027
Last update
Aug 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03611270
Lead sponsor
SoniVie Inc.
Responsible party
Sponsor
First posted
Aug 2, 2018
Start date
Nov 30, 2018
Primary completion
Dec 1, 2023 (estimated)
Completion
Jul 2027 (estimated)
Last update
Aug 21, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion